+39 02 610346.1 - info@newron.com

Robert Holland

Robert Holland

Robert served at AstraZeneca as a member of the R&D Leadership Team with roles including: Vice President & Head, Personalised HealthCare & Biomarkers 2010 to 2012: and Vice President & Head, Neuroscience Therapeutic Area 2005-2010.  Currently, he is Senior Clinical Fellow at Sosei Heptares.  Until 2018 he was Executive Director, Early Clinical Development Consulting Ltd., a consultant to the Wellcome Trust and Chief Medical Officer of Oxford Gene Technology. Previously, Robert held positions in research and clinical development at Upjohn, Solvay, Rhone Poulenc and the Wellcome Foundation and has served as a Non-Executive Director at Karolinska Development AB. He has extensive experience in the discovery, development and commercialization of drugs for both neurological and psychiatric conditions and in the in-licensing and successful co-development of medicines originating from partner companies. He has been a lecturer at The Royal London Hospital and at Merton College, Oxford in human physiology and in anatomy, respectively. He holds an MD and a PhD from the University of OxfordRobert is a member of Newron’s Research and Development Committee. Robert is British.